CABR™ CAR-T Cell Detection ISH Probes

What is CAR-T cell therapy? It is a type of treatment mainly about isolating the patient's T cells and genetically engineering the cells to express chimeric antigen receptors (CARs), which can recognize a specific tumor associated antigen, such as CD19, BCMA and CD20. After infusing the engineered CAR-T cells into the body, the tumor cells are targeted efficiently. Two landmark events occurred for CAR-T cell therapy in 2017: two anti-CD19 CAR-T cells were approved by FDA for the therapy of acute lymphoblastic leukemia (ALL) and relapsed or refractory large B-cell lymphoma, respectively. From then, increasing number of researchers have been dedicated to CAR-T cell therapy research around the world.

Toxicity Assessment of CAR-T Cells

"On-target/off-tumor" toxicity was an expected side effect of CAR T therapy from the outset. In Situ Hybridization (ISH) is a great method that can be utilized to identify novel CAR-T cell targets and subsequently qualify monoclonal antibodies directed against those targets for immunohistochemistry. ISH can be used to predict CAR-T cell target organ toxicity in preclinical models.

Disrtribution Assessment of CAR-T Cells

The distribution of CAR-T cells in the tumor and in the body is important for assessing the antitumor effect and safety of the injected CAR-T in vivo, while observing the antitumor effect. ISH can be used to evaluate the CAR expression.

Figure 1. Multifocal CAR cell infiltrates associated with increased expression of IFN-γ, CD25 and CD134 and tumor cell EGFRvIII expression. Post EGFRvIII-CAR treatment biopsies of glipbalstoma multiforme (6 days).

Creative Bioarray has successfully developed CAR-T Cell Detection ISH probes, covering most of the investigational CAR-T cell therapy targets. The probes with highest quality with bright, easy to interpret signals. Therefore, CAR-T cell target ISH probes in Creative Bioarray are the first choice for your project

See All CABR™CAR-T Cell Detection ISH Probe >>>